Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial

Chest

Volumn 150, Issue 1, 2016, Pages 123-130

  Cosío, Borja G ^a,h   Shafiek, Hanaa ^a,b   Iglesias, Amanda ^a,h   Yanez, Aina ^a   Córdova, Rocío ^a   Palou, Alexandre ^a   Rodriguez Roisin, Robert ^c,h   Peces Barba, Germán ^d,h   Pascual, Sergi ^e,h   Gea, Joaquim ^e,h   Sibila, Oriol ^f,h   Barnes, Peter J ^g   Agusti, Alvar ^c,h  

^a HEALTH RESEARCH INSTITUTE OF THE BALEARIC ISLANDS IDISBA   (Spain)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^e INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

airway inflammation; COPD; HDAC; inflammation; steroid response; theophylline

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; HISTONE DEACETYLASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; THEOPHYLLINE; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MACROPHAGE; MALE; MONOCYTE; MULTICENTER STUDY; OXYGEN THERAPY; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BLOOD; COMBINATION DRUG THERAPY; DOSE RESPONSE; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PILOT STUDY; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENT DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYMPTOM FLARE UP; THEOPHYLLINE; TREATMENT OUTCOME;

EID: 84990065843     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.04.011     Document Type: Article

References (24)

1. 1 Vestbo, J., Hurd, S.S., Agusti, A.G., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187:4 (2013), 347–365.
2. 2 Barnes, P.J., Corticosteroid resistance in airway disease. Proc Am Thorac Soc 1:3 (2004), 264–268.
3. 3 Barnes, P.J., Ito, K., Adcock, I.M., Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363:9410 (2004), 731–733.
4. 4 Adcock, I.M., Cosio, B., Tsaprouni, L., Barnes, P.J., Ito, K., Redox regulation of histone deacetylases and glucocorticoid-mediated inhibition of the inflammatory response. Antioxid Redox Signal 7:1-2 (2005), 144–152.
5. 5 Tomita, K., Barnes, P.J., Adcock, I.M., The effect of oxidative stress on histone acetylation and IL-8 release. Biochem Biophys Res Commun 301:2 (2003), 572–577.
6. 6 Cosio, B.G., Jahn, A., Iglesias, A., Shafiek, H., Busquets, X., Agusti, A., Haemophilus influenzae induces steroid-resistant inflammatory responses in COPD. BMC Pulm Med, 15, 2015, 157.
7. 7 Cosio, B.G., Tsaprouni, L., Ito, K., Jazrawi, E., Adcock, I.M., Barnes, P.J., Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200:5 (2004), 689–695.
8. 8 Cosio, B.G., Iglesias, A., Rios, A., et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 64:5 (2009), 424–429.
9. 9 To, Y., Ito, K., Kizawa, Y., et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 182:7 (2010), 897–904.
10. 10 Zhou, Y., Wang, X., Zeng, X., et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 11:5 (2006), 603–610.
11. 11 Agusti, A., Soler, J.J., Molina, J., et al. Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations?. COPD 9:5 (2012), 492–498.
12. 12 Rodriguez-Roisin, R., Toward a consensus definition for COPD exacerbations. Chest 117:5 suppl 2 (2000), 398S–401S.
13. 13 Barnes, P.J., Theophylline. Am J Respir Crit Care Med 188:8 (2013), 901–906.
14. 14 Rabe, K.F., Magnussen, H., Dent, G., Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 8:4 (1995), 637–642.
15. 15 Mascali, J.J., Cvietusa, P., Negri, J., Borish, L., Anti-inflammatory effects of theophylline: modulation of cytokine production. Ann Allergy Asthma Immunol 77:1 (1996), 34–38.
16. 16 Yasui, K., Hu, B., Nakazawa, T., Agematsu, K., Komiyama, A., Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 100:7 (1997), 1677–1684.
17. 17 Tomita, K., Chikumi, H., Tokuyasu, H., et al. Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline. Naunyn Schmiedebergs Arch Pharmacol 359:4 (1999), 249–255.
18. 18 Culpitt, S.V., De Matos, C., Russell, R.E., Donnelly, L.E., Rogers, D.F., Barnes, P.J., Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165:10 (2002), 1371–1376.
19. 19 Ford, P.A., Durham, A.L., Russell, R.E., Gordon, F., Adcock, I.M., Barnes, P.J., Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137:6 (2010), 1338–1344.
20. 20 Hirano, T., Yamagata, T., Gohda, M., et al. Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline. Thorax 61:9 (2006), 761–766.
21. 21 Ito, K., Lim, S., Caramori, G., et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 99:13 (2002), 8921–8926.
22. 22 Ito, K., Ito, M., Elliott, W.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352:19 (2005), 1967–1976.
23. 23 Kersul, A.L., Iglesias, A., Rios, A., et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 47:4 (2011), 176–183.
24. 24 Zhu, B., Haghi, M., Goud, M., Young, P.M., Traini, D., The formulation of a pressurized metered dose inhaler containing theophylline for inhalation. Eur J Pharm Sci 76 (2015), 68–72.